Pharmacoeconomic review report: Travoprost 0.003% (Izba) (Novartis Pharmaceuticals Canada Inc. on behalf of Icon Canada Inc.)
Polyquaternium-1-preserved travoprost 0.003% ophthalmic solution (Izba, travoprost 0.003% PQ) is a prostaglandin analogue (PGA) indicated for the reduction of intraocular pressure (IOP) among patients with open-angle glaucoma (OAG) or ocular hypertension. Travoprost 0.003% PQ is available as a topic...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
November 2017, 2017
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Polyquaternium-1-preserved travoprost 0.003% ophthalmic solution (Izba, travoprost 0.003% PQ) is a prostaglandin analogue (PGA) indicated for the reduction of intraocular pressure (IOP) among patients with open-angle glaucoma (OAG) or ocular hypertension. Travoprost 0.003% PQ is available as a topical ophthalmic solution with a recommended dose of one drop in the affected eye(s) per day. The manufacturer is requesting reimbursement per indication and has submitted a market price of $20.13 per 5 mL bottle |
|---|---|
| Item Description: | "Version: Final." |
| Physical Description: | 1 PDF file (18 pages) |